

ASX ANNOUNCEMENT

2 August 2021

CAPITAL RAISE

Brisbane, Australia and Minneapolis, USA.

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) is pleased to announce the placement of 1.125m new Ordinary shares (New Shares) to sophisticated investors at \$8.00 per share raising a total \$9 million. The proceeds of the Placement will be used for working capital predominantly related to the development of DurAVR™, the Company's 3D single-piece aortic valve for the treatment of Aortic Stenosis.

Additionally, the investors will receive three unlisted 4-year Options for every five New Shares issued (totaling 675,000 Options), with an exercise price of \$10.00. These Options are subject to shareholder approval under ASX listing rule 7.1. If shareholder approval is not provided, investors will instead receive a cash payment of \$1.25 per Option.

Total fees payable to brokers and agents for facilitating the capital raising is 7% of the gross proceeds raised in the placement. Subject to shareholder approval under ASX listing rule 7.1 Anteris has agreed to issue the Lead Manager, Evolution Capital Advisors Pty Ltd 500,000 Options. The Options will be unlisted 4-year Options exercisable at \$10.00. If shareholder approval to issue the Options is not granted, a cash payment equivalent to \$1.25 per Option is payable.

The issue of New Shares will be made under the Company's available placement capacity under Listing Rules 7.1 and 7.1A and so does not require shareholder approval.

Shareholder approval to issue the options to investors and Evolution will be sought at an extraordinary general meeting to be held over the coming quarter.

"With this new capital round we will continue to deliver on our plan of achieving EFS approval in 2021 as well as advancing our Coronary Artery Bypass Graft and surgical valve projects," Anteris Chief Executive Officer Mr Wayne Paterson said.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Trina Raymond

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 420 316 449

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech